Skip to main content
. 2017 Jan 17;8(7):10871–10882. doi: 10.18632/oncotarget.14719

Figure 3. Forest plots analyzing the efficacy of ATG in allo-HCT.

Figure 3

Figure 3

Figure 3

(1) Overall aGVHD, (2) aGVHD (grade III-IV), (3) Overall cGVHD, (4) Extensive cGVHD, (5) Relapse, (6) Infections, (7) 100-day TRM, (8) 1-year OS, (9) 2-year OS.